Laboratoires Pierre Fabre
This sponsor has funded 3 studies across 6 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 2679 | Finalised | SURVEILLANCE STUDY OF PHOTOCONTACT DERMATITIS LEADING TO HOSPITALIZATION IN EUROPE WITH A SPECIAL FOCUS ON TOPICAL KETOPROFEN AND OTHER TOPICAL... | Yes | No |
| 10726 | Finalised | Observational study of post-myocardial infarction with a long follow-up (EOLE) | No | No |
| 41584 | Ongoing | Multicentre, multi-country, prospective, observational, post-authorisation safety study to describe the incidence of discontinuation due to diarrhoea... | No | No |
PAS by Risk Management Plan (RMP) requirement
Laboratoires Pierre Fabre
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Laboratoires Pierre Fabre
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Laboratoires Pierre Fabre
6 Study countries specified are the following:
- Austria
- Czechia
- France
- Germany
- Italy
- United Kingdom